Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH Analogue
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Breast Cancer
Conditions
Early Breast Cancer
Trial Timeline
Oct 2, 2020 → Feb 28, 2033
NCT ID
NCT04293393About Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH Analogue
Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH Analogue is a phase 2 stage product being developed by Eli Lilly for Early Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04293393. Target conditions include Early Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04293393 | Phase 2 | Active |
Competing Products
20 competing products in Early Breast Cancer